Due to the overall positive response to treatment reported in this study, a phase II clinical trial (NCT01320085) investigating the safety and efficacy of MEK162 in patients with advanced or unresectable metastatic malignant melanoma, harboring BRAFV600 or NRAS mutations, is currently underway. Here, NRAS is linked to melanoma.